Related references
Note: Only part of the references are listed.Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations
Don Husereau et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2022)
GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 (vol 17, pg 954, 2018)
Ali H. Mokdad
LANCET NEUROLOGY (2021)
Cost-Effectiveness of Erenumab for the Preventive Treatment of Migraine in Patients with Prior Treatment Failures in Sweden
Ronan Mahon et al.
PHARMACOECONOMICS (2021)
Updated cost-effectiveness analysis of onabotulinumtoxinA for the prevention of headache in adults with chronic migraine who have previously received three or more preventive treatments in the UK
Georgia Hollier-Hann et al.
JOURNAL OF MEDICAL ECONOMICS (2020)
Economic evaluations in migraine: systematic literature review and a novel approach
Ronan Mahon et al.
JOURNAL OF MEDICAL ECONOMICS (2020)
Economic consequences of migraine in Sweden and implications for the cost-effectiveness of onabotulinumtoxinA (Botox) for chronic migraine in Sweden and Norway
Amanda Hansson-Hedblom et al.
JOURNAL OF HEADACHE AND PAIN (2020)
Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019
T. J. Steiner et al.
JOURNAL OF HEADACHE AND PAIN (2020)
Cost-Effectiveness Analysis of Erenumab Versus OnabotulinumtoxinA for Patients with Chronic Migraine Attacks in Greece
Theodoros V. Giannouchos et al.
CLINICAL DRUG INVESTIGATION (2019)
Associations Between Headache-Free Days and Patient-Reported Outcomes Among Migraine Patients: A Cross-Sectional Analysis of Survey Data in Europe
Michael J. Doane et al.
PAIN AND THERAPY (2019)
Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition
Jes Olesen
CEPHALALGIA (2018)
Genetic association of HCRTR2, ADH4 and CLOCK genes with cluster headache: a Chinese population-based case-control study
Zhiliang Fan et al.
JOURNAL OF HEADACHE AND PAIN (2018)
Estimating, the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective
Richard B. Lipton et al.
JOURNAL OF MEDICAL ECONOMICS (2018)
Cost-effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine: Results from the US societal and payer perspectives
Matthew Sussman et al.
CEPHALALGIA (2018)
Changes in health in the countries of the UK and 150 English Local Authority areas 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016
Nicholas Steel et al.
LANCET (2018)
Global, regional, and national burden of meningitis, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016
Joseph Raymond Zunt et al.
LANCET NEUROLOGY (2018)
Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016
Lars Jacob Stovner et al.
LANCET NEUROLOGY (2018)
Economic Burden and Costs of Chronic Migraine
Michel Lanteri-Minet
CURRENT PAIN AND HEADACHE REPORTS (2013)
The cost-effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK
Anthony J. Batty et al.
JOURNAL OF MEDICAL ECONOMICS (2013)
Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: A systematic review
Michel Lanteri-Minet et al.
CEPHALALGIA (2011)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
ANNALS OF INTERNAL MEDICINE (2009)
Cost-effectiveness of migraine prevention: The case of topiramate in the UK
J. S. Brown et al.
CEPHALALGIA (2006)
Cost-effectiveness of topiramate in migraine prevention: Results from a pharmacoeconomic model of topiramate treatment
JS Brown et al.
HEADACHE (2005)
Cost-effectiveness of antiepileptic drugs in migraine prophylaxis
JU Adelman et al.
HEADACHE (2002)
Share Paper
